BioWorld

Oct. 31, 2002

View Archived Issues

Inspire Says INS365 NDA Filing Not Far Off; Stock Jumps 53%

Inspire Pharmaceuticals Inc. said following a productive meeting with the FDA, it has decided to compile existing data from three trials of its dry-eye product, INS365 Ophthalmic, and submit it for regulatory approval. (BioWorld Today) Read More

Patience Is Secret Of Herpes Virus Long-Term Latency Strategy, Not Molecular Maneuverings In People

Read More

Neurogenetics Closes Series B With Second Tranche Of $10M

Read More

Other News To Note

Read More

Correction

Read More

Serono, IVAX Sign To Develop Cladribine As Oral MS Treatment

Read More

U.S. Patent Disclosures

Read More

Kemia Closes Potential $16.5M Series A To Fund Clinical Trials

Read More